End-to-end oncology drug developer with 20 years of hands-on experience
Led Antican® from invention to regulatory approval across 3 countries
With patents in 32+ nations and top honors in related fields internationally

Our core mission is to bridge the gap between complex immunology and deployable clinical solutions
We specialize in TME Source Modulation, focusing on non-toxic PD-1 enhancers

By modulating MDSCs and empowering T-cell killing at the source
We unlock the full potential of existing immunotherapies across all clinical settings
Designed for seamless integration into community oncology settings worldwide

We have not forgotten our responsibility toward animal health
We welcome strategic partnerships to ensure these validated therapies
continue to benefit the global veterinary community